1
STATE OF OKLAHOMA
1
2
1st Session of the 60th Legislature (2025)
2
3
SENATE BILL 941 By: Deevers
3
4
4
5
5
6
AS INTRODUCED
6
7
An Act relating to pharmaceutical products; defining
7
terms; requiring manufacturers of pharmaceutical
8
products to publish certain list of ingredients;
8
specifying certain inclusions; clarifying
9
applicability; requiring certain submission and
9
publication; providing administrative, civil, and
10
criminal penalties and remedies; granting certain
10
protection; requiring establishment of certain
11
reporting system; preempting certain rulemaking;
11
providing certain construction; providing for
12
codification; and providing an effective date.
12
13
13
14
14
15
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
15
16
SECTION 1. NEW LAW A new section of law to be codified
16
17
in the Oklahoma Statutes as Section 9002.1 of Title 63, unless there
17
18
is created a duplication in numbering, reads as follows:
18
19
As used in this act:
19
20
1. “Pharmaceutical product” means any drug or device as defined
20
21
in Section 353.1 of Title 59 of the Oklahoma Statutes including
21
22
prescription drugs, over-the-counter medications, vaccines, and
22
23
products intended for research purposes;
23
24
2. “Ingredient” includes:
24
Req. No. 1363 Page 1

1
a. all active and inactive components,
1
2
b. biological materials, such as mRNA, DNA from human or
2
3
animal sources, and viral vectors,
3
4
c. synthetic materials, including lipids, nanotechnology
4
5
components, and polymers, and
5
6
d. adjuvants, preservatives, stabilizers, and other
6
7
additives; and
7
8
3. “Manufacturer” means any person or entity engaged in the
8
9
production, preparation, propagation, compounding, or processing of
9
10
pharmaceutical products, as defined in Section 353.1 of Title 59 of
10
11
the Oklahoma Statutes.
11
12
SECTION 2. NEW LAW A new section of law to be codified
12
13
in the Oklahoma Statutes as Section 9002.2 of Title 63, unless there
13
14
is created a duplication in numbering, reads as follows:
14
15
A. Manufacturers of pharmaceutical products, including those
15
16
intended exclusively for research purposes, shall publish a complete
16
17
and detailed list of all ingredients for each product.
17
18
1. The list shall include:
18
19
a. the chemical and common names of all active, inactive,
19
20
biological, and synthetic ingredients,
20
21
b. the origin of any biological materials, specifying
21
22
whether they are derived from human, animal, or
22
23
synthetic sources,
23
24
c. the purpose of each ingredient, and
24
Req. No. 1363 Page 2

1
d. the quantity or concentration of each ingredient,
1
2
including trace elements and residuals.
2
3
2. For products containing mRNA or other gene-based technology,
3
4
the disclosure shall specify:
4
5
a. the sequence and source of any nucleic acids, and
5
6
b. the delivery mechanism, including synthetic carriers
6
7
such as lipid nanoparticles.
7
8
B. The ingredient information shall be:
8
9
1. Submitted to the State Board of Pharmacy;
9
10
2. Published publicly on a manufacturer-maintained website; and
10
11
3. Included in product labeling and marketing materials.
11
12
C. The responsibility to disclose all ingredients or components
12
13
of any pharmaceutical product, medical treatment, or mandate shall
13
14
remain unchanged regardless of whether a national emergency is
14
15
declared by the President of the United States or Congress. The
15
16
rights of individuals shall not be suspended, abridged, or infringed
16
17
during any declared emergency.
17
18
SECTION 3. NEW LAW A new section of law to be codified
18
19
in the Oklahoma Statutes as Section 9002.3 of Title 63, unless there
19
20
is created a duplication in numbering, reads as follows:
20
21
A. Noncompliance with the provisions of this act shall result
21
22
in the following penalties:
22
23
1. Fines up to Fifty Thousand Dollars ($50,000) per violation,
23
24
per product; and
24
Req. No. 1363 Page 3

1
2. Suspension or revocation of the right to distribute or sell
1
2
the noncompliant pharmaceutical product within this state until
2
3
compliance is achieved.
3
4
B. Enhanced penalties for repeated or willful violations shall
4
5
be assessed as follows:
5
6
1. Escalating fines:
6
7
a. on a second violation: fines up to One Hundred
7
8
Thousand Dollars ($100,000.00) per product, and
8
9
b. on a third or subsequent violation: fines up to Two
9
10
Hundred Fifty Thousand Dollars ($250,000.00) per
10
11
product;
11
12
2. Prohibition of operations: For continued noncompliance, the
12
13
manufacturer may be prohibited from distributing or selling any
13
14
pharmaceutical products in this state for up to one (1) year; and
14
15
3. Criminal liability: Repeated or intentional
15
16
misrepresentation or omission of ingredient information is a
16
17
misdemeanor crime punishable by up to one (1) year imprisonment.
17
18
C. The following civil remedies shall be available:
18
19
1. Private right to civil action: Any individual or group
19
20
harmed by noncompliance with this act, including misrepresentation
20
21
or omission of ingredient information, may bring a civil lawsuit
21
22
against the manufacturer for damages including, but not limited to:
22
23
a. economic damages including, but not limited to,
23
24
medical expenses or financial losses,
24
Req. No. 1363 Page 4

1
b. noneconomic damages including, but not limited to,
1
2
pain and suffering or emotional distress, and
2
3
c. punitive damages, as appropriate under Oklahoma law.
3
4
2. Class action suit: Affected individuals may form a class to
4
5
seek collective remedy in cases of widespread harm resulting from
5
6
noncompliance.
6
7
D. The State of Oklahoma may seek injunctive relief to compel
7
8
compliance or halt the distribution and sale of noncompliant
8
9
pharmaceutical products.
9
10
E. Individuals who report violations of this act by
10
11
manufacturers shall be protected from retaliation under applicable
11
12
whistleblower statutes and may be entitled to a percentage of fines
12
13
collected as a result of their report.
13
14
F. The State Board of Pharmacy shall establish a reporting
14
15
system for individuals to file complaints regarding suspected
15
16
violations of this act, with such reports forwarded to the
16
17
Legislature for review and potential enforcement action.
17
18
SECTION 4. NEW LAW A new section of law to be codified
18
19
in the Oklahoma Statutes as Section 9002.4 of Title 63, unless there
19
20
is created a duplication in numbering, reads as follows:
20
21
The Legislature shall retain exclusive rule-making authority to
21
22
implement and enforce the provisions of this act.
22
23
23
24
24
Req. No. 1363 Page 5

1
SECTION 5. NEW LAW A new section of law to be codified
1
2
in the Oklahoma Statutes as Section 9002.5 of Title 63, unless there
2
3
is created a duplication in numbering, reads as follows:
3
4
To the extent any laws conflict with this act, this act shall
4
5
govern.
5
6
SECTION 6. This act shall become effective January 1, 2026.
6
7
7
8
60-1-1363 DC 1/19/2025 5:46:25 AM
8
9
9
10
10
11
11
12
12
13
13
14
14
15
15
16
16
17
17
18
18
19
19
20
20
21
21
22
22
23
23
24
24
Req. No. 1363 Page 6

[DELETED:  P B D]
[DELETED:  P a b s a t t t]
[DELETED:  P t t t]
[DELETED:  P o o e]
[DELETED:  P n p]
[DELETED:  P D 1]